136
Participants
Start Date
November 30, 2011
Primary Completion Date
May 31, 2013
Study Completion Date
May 31, 2013
ACZ885
canakinumab 150 mg s.c., given on demand upon new flares
Triamcinolone acetonide 40 mg
Participants received 40 mg intramuscular (IM)
Novartis Investigative Site, Darlinghurst
Novartis Investigative Site, Tallinn
Novartis Investigative Site, Tallinn
Novartis Investigative Site, Newport News
Novartis Investigative Site, Danville
Novartis Investigative Site, Hickory
Novartis Investigative Site, Columbia
Novartis Investigative Site, Charleston
Novartis Investigative Site, Charleston
Novartis Investigative Site, Varnville
Novartis Investigative Site, Decatur
Novartis Investigative Site, Löhne
Novartis Investigative Site, Jupiter
Novartis Investigative Site, Clearwater
Novartis Investigative Site, Mobile
Novartis Investigative Site, Clarksville
Novartis Investigative Site, Johnson City
Novartis Investigative Site, Bristol
Novartis Investigative Site, Magdeburg
Novartis Investigative Site, Jackson
Novartis Investigative Site, Jackson
Novartis Investigative Site, Willoughby Hills
Novartis Investigative Site, Dayton
Novartis Investigative Site, Troy
Novartis Investigative Site, Flint
Novartis Investigative Site, Kaunas
Novartis Investigative Site, Missoula
Novartis Investigative Site, Overland Park
Novartis Investigative Site, Topeka
Novartis Investigative Site, Wichita
Novartis Investigative Site, Omaha
Novartis Investigative Site, Zaporizhzhya
Novartis Investigative Site, Metairie
Novartis Investigative Site, Opelousas
Novartis Investigative Site, Augsburg
Novartis Investigative Site, Uzhhorod
Novartis Investigative Site, Norwalk
Novartis Investigative Site, Pasadena
Novartis Investigative Site, San Diego
Novartis Investigative Site, Klaipėda
Novartis Investigative Site, Tustin
Novartis Investigative Site, Moscow
Novartis Investigative Site, Yaroslavl
Novartis Investigative Site, Petrozavodsk
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Yekaterinburg
Novartis Investigative Site, Anniston
Novartis Investigative Site, Freehold
Novartis Investigative Site, St. John's
Novartis Investigative Site, St. John's
Novartis Investigative Site, St. John's
Novartis Investigative Site, Sainte-Foy
Novartis Investigative Site, Valmiera
Novartis Investigative Site, Šiauliai
Novartis Investigative Site, Vilnius
Novartis Investigative Site, Vilnius
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY